Fatigue and neuromuscular diseases;Fatigue et affections neuromusculaires

Annales de Readaptation et de Medecine Physique

Volumn 49, Issue 6, 2006, Pages 289-300

  Feasson L ^a,b   Camdessanche J P ^a,b   El Mandhi, L ^a,b   Calmels, P ^a,b   Millet, G Y ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ELECTROMYOGRAPHY; EXERCISE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FATIGUE; GUILLAIN BARRE SYNDROME; HUMAN; MITOCHONDRIAL MYOPATHY; MUSCLE FORCE; MUSCULAR DYSTROPHY; MYASTHENIA GRAVIS; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NEUROPATHIC JOINT DISEASE; PERIPHERAL NEUROPATHY; POSTPOLIOMYELITIS SYNDROME; QUESTIONNAIRE; RATING SCALE;

FATIGUE; HUMANS; NEUROMUSCULAR DISEASES; QUESTIONNAIRES;

EID: 33745989621     PISSN: 01686054     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annrmp.2006.04.015     Document Type: Article

References (95)

1. Abresch R.T., Carter G.T., Jensen M.P., and Kilmer D.D. Assessment of pain and healthrelated quality of life in slowly progressive neuromuscular disease. Am. J. Hosp. Palliat. Care 19 1 (2002) 39-48
2. Andersson T., and Siden A. A clinical study of the Guillain-Barre syndrome. Acta Neurol. Scand. 66 3 (1982) 316-327
3. Ansved T. Muscle training in muscular dystrophies. Acta Physiol. Scand. 171 3 (2001) 359-366
4. Argov Z., Bank W.J., Maris J., and Chance B. Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy. Neurology 37 11 (1987) 1720-1724
5. Argov Z., Bank W.J., Maris J., Peterson P., and Chance B. Bioenergetic heterogeneity of human mitochondrial myopathies: phosphorus magnetic resonance spectroscopy study. Neurology 37 2 (1987) 257-262
6. Behm D.G., and St-Pierre D.M. The effects of strength training and disuse on the mechanisms of fatigue. Sports Med. 25 3 (1998) 173-189
7. Bendahan D., Confort-Gouny S., Kozak-Ribbens G., and Cozzone P.J. 31-P NMR characterization of the metabolic anomalies associated with the lack of glycogen phosphorylase activity in human forearm muscle. Biochem. Biophys. Res. Commun. 185 1 (1992) 16-21
8. Bruno R.L., Sapolsky R., Zimmerman J.R., and Frick N.M. Pathophysiology of a central cause of postpolio fatigue. Ann. NY Acad. Sci. 753 (1995) 257-275
9. Béthoux F., and Calmels P. Outils génériques d'évaluation de la qualité de vie. In: Béthoux F., and Calmels P. (Eds). Guide des outils d'évaluation en médecine physique et de réadaptation (2003), Frison Roche, Paris 81-89
10. Carter G.T., Weiss M.D., Lou J.S., Jensen M.P., Abresch R.T., Martin T.K., et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am. J. Hosp. Palliat. Care 22 1 (2005) 55-59
11. Chaudhuri A., and Behan P.O. Fatigue in neurological disorders. Lancet 363 9413 (2004) 978-988
12. Chetlin R.D., Gutmann L., Tarnopolsky M., Ullrich I.H., and Yeater R.A. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Arch. Phys. Med. Rehabil. 85 8 (2004) 1217-1223
13. Chetlin R.D., Gutmann L., Tarnopolsky M.A., Ullrich I.H., and Yeater R.A. Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle Nerve 30 1 (2004) 69-76
14. Drory V.E., Goltsman E., Reznik J.G., Mosek A., and Korczyn A.D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 191 1-2 (2001) 133-137
15. Dugan S.A., and Frontera W.R. Muscle fatigue and muscle injury. Phys. Med. Rehabil. Clin. N. Am. 11 2 (2000) 385-403
16. Edwards R.H., Chapman S.J., Newham D.J., and Jones D.A. Practical analysis of variability of muscle function measurements in Duchenne muscular dystrophy. Muscle Nerve 10 1 (1987) 6-14
17. Elliot D.L., Buist N.R., Goldberg L., Kennaway N.G., Powell B.R., and Kuehl K.S. Metabolic myopathies: evaluation by graded exercise testing. Medicine (Baltimore) 68 3 (1989) 163-172
18. Emeryk B., Rowinska-Marcinska K., Nowak-Michalska T., and Sawicka E. Muscular fatigability in mitochondrial myopathies. An electrophysiological study. Electromyogr. Clin. Neurophysiol. 32 4-5 (1992) 235-245
19. Finsterer J. Mitochondriopathies. Eur. J. Neurol. 11 3 (2004) 163-186
20. Fisk J.D., Ritvo P.G., Ross L., Haase D.A., Marrie T.J., and Schlech W.F. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18 Suppl 1 (1994) S79-S83
21. Forsberg A., Press R., Einarsson U., de Pedro-Cuesta J., and Widen Holmqvist L. Impairment in Guillain-Barre syndrome during the first 2 years after onset: a prospective study. J. Neurol. Sci. 227 1 (2004) 131-138
22. Fowler Jr. W.M. Role of physical activity and exercise training in neuromuscular diseases. Am. J. Phys. Med. Rehabil. 81 11 Suppl (2002) S187-S195
23. Garssen M.P., Blok J.H., van Doorn P.A., and Visser G.H. Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barre syndrome patients. Muscle Nerve 33 2 (2006) 177-182
24. Garssen M.P., Bussmann J.B., Schmitz P.I., Zandbergen A., Welter T.G., Merkies I.S., et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 63 12 (2004) 2393-2395
25. Garssen M.P., Schmitz P.I., Merkies I.S., Jacobs B.C., van der Meche F.G., and van Doorn P.A. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J. Neurol. Neurosurg. Psychiatry 77 1 (2006) 61-65
26. Giannesini B., Cozzone P.J., and Bendahan D. Non-invasive investigations of muscular fatigue: metabolic and electromyographic components. Biochimie 85 9 (2003) 873-883
27. Gledhill J.A., Rodary C., Mahe C., and Laizet C. French validation of the revised Piper Fatigue Scale. Rech. Soins Infirm. 68 (2002) 50-65
28. Guinvarch S., Bérard C., and Calmels P. Affections neuromusculaires. In: Béthoux F., and Calmels P. (Eds). Guide des outils d'évaluation en médecine physique et de réadaptation (2003), Frison Roche, Paris 269-283
29. Hartung H.P., van der Meche F.G., and Pollard J.D. Guillain-Barre syndrome, CIDP and other chronic immune-mediated neuropathies. Curr. Opin. Neurol. 11 5 (1998) 497-513
30. Hogrel J.Y., Laforet P., Ben Yaou R., Chevrot M., Eymard B., and Lombes A. A nonischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 56 12 (2001) 1733-1738
31. Horemans H.L., Beelen A., Nollet F., Jones D.A., and Lankhorst G.J. Reproducibility of maximal quadriceps strength and its relationship to maximal voluntary activation in postpoliomyelitis syndrome. Arch. Phys. Med. Rehabil. 85 8 (2004) 1273-1278
32. Horemans H.L., Nollet F., Beelen A., and Lankhorst G.J. A comparison of 4 questionnaires to measure fatigue in postpoliomyelitis syndrome. Arch. Phys. Med. Rehabil. 85 3 (2004) 392-398
33. Jackson M.J., Round J.M., Newham D.J., and Edwards R.H. An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy. Muscle Nerve 10 1 (1987) 15-21
34. John T.J. The final stages of the global eradication of polio. N. Engl. J. Med. 343 11 (2000) 806-807
35. Kalkman J.S., Schillings M.L., van der Werf S.P., Padberg G.W., Zwarts M.J., van Engelen B.G., et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J. Neurol. Neurosurg. Psychiatry 76 10 (2005) 1406-1409
36. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 4 (2004) 484-505
37. Kent-Braun J.A., and Miller R.G. Central fatigue during isometric exercise in amyotrophic lateral sclerosis. Muscle Nerve 23 6 (2000) 909-914
38. Kent-Braun J.A., Walker C.H., Weiner M.W., and Miller R.G. Functional significance of upper and lower motor neuron impairment in amyotrophic lateral sclerosis. Muscle Nerve 21 6 (1998) 762-768
39. Kittiwatanapaisan W., Gauthier D.K., Williams A.M., and Oh S.J. Fatigue in Myasthenia Gravis patients. J. Neurosci. Nurs. 35 2 (2003) 87-93 (106)
40. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46 10 (1989) 1121-1123
41. Kurillo G., Zupan A., and Bajd T. Force tracking system for the assessment of grip force control in patients with neuromuscular diseases. Clin. Biomech. (Bristol, Avon) 19 10 (2004) 1014-1021
42. Laberge L., Gagnon C., Jean S., and Mathieu J. Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J. Neurol. Neurosurg. Psychiatry 76 10 (2005) 1403-1405
43. Lindeman E., Spaans F., Reulen J., Leffers P., and Drukker J. Progressive resistance training in neuromuscular patients. Effects on force and surface EMG. J. Electromyogr. Kinesiol. 9 6 (1999) 379-384
44. Lindeman E., Spaans F., Reulen J.P., Leffers P., and Drukker J. Surface EMG of proximal leg muscles in neuromuscular patients and in healthy controls. Relations to force and fatigue. J. Electromyogr. Kinesiol. 9 5 (1999) 299-307
45. Lou J.S. Approaching fatigue in neuromuscular diseases. Phys. Med. Rehabil. Clin. N. Am. 16 4 (2005) 1063-1079 (xi)
46. Lou J.S., Reeves A., Benice T., and Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology 60 1 (2003) 122-123
47. Maddison P., and Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst. Rev. 2 (2005) (CD003279)
48. Maselli R.A., and Bakshi N. AAEM case report 16. Botulism. American association of electrodiagnostic medicine. Muscle Nerve 23 7 (2000) 1137-1144
49. Merkies I.S., Schmitz P.I., Samijn J.P., van der Meche F.G., and van Doorn P.A. Fatigue in immune-mediated polyneuropathies. European inflammatory neuropathy cause and treatment (INCAT) group. Neurology 53 8 (1999) 1648-1654
50. Mermier C.M., Schneider S.M., Gurney A.B., Weingart H.M., and Wilmerding M.V. Preliminary results: Effect of whole-body cooling in patients with myasthenia gravis. Med. Sci. Sports Exerc. 38 1 (2006) 13-20
51. Merton P.A. Voluntary strength and fatigue. J. Physiol. 123 3 (1954) 553-564
52. Meythaler J.M. Rehabilitation of Guillain-Barre syndrome. Arch. Phys. Med. Rehabil. 78 8 (1997) 872-879
53. Miller R.G. Role of fatigue in limiting physical activities in humans with neuromuscular diseases. Am. J. Phys. Med. Rehabil. 81 11 Suppl (2002) S99-S107
54. Miller R.G., Kent-Braun J.A., Sharma K.R., and Weiner M.W. Mechanisms of human muscle fatigue. Quantitating the contribution of metabolic factors and activation impairment. Adv. Exp. Med. Biol. 384 (1995) 195-210
55. Miller R.G., Rosenberg J.A., Gelinas D.F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidencebased review). Muscle Nerve 22 8 (1999) 1104-1118
56. Miller R.G., Rosenberg J.A., Gelinas D.F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidencebased review): report of the quality standards subcommittee of the American academy of neurology: ALS practice parameters task force. Neurology 52 7 (1999) 1311-1323
57. Millet G.Y., and Lepers R. Alterations of neuromuscular function after prolonged running, cycling and skiing exercises. Sports Med. 34 2 (2004) 105-116
58. Nollet F., and Beelen A. Strength assessment in postpolio syndrome: validity of a handheld dynamometer in detecting change. Arch. Phys. Med. Rehabil. 80 10 (1999) 1316-1323
59. Nollet F., Beelen A., Prins M.H., de Visser M., Sargeant A.J., Lankhorst G.J., et al. Disability and functional assessment in former polio patients with and without postpolio syndrome. Arch. Phys. Med. Rehabil. 80 2 (1999) 136-143
60. Ochs C.W., Bradley R.J., Katholi C.R., Byl N.N., Brown V.M., Jones L.L., et al. Symptoms of patients with myasthenia gravis receiving treatment. J. Med. 29 1-2 (1998) 1-12
61. Paul R.H., Cohen R.A., Goldstein J.M., and Gilchrist J.M. Fatigue and its impact on patients with Myasthenia Gravis. Muscle Nerve 23 9 (2000) 1402-1406
62. Pfeiffer G., Wicklein E.M., Ratusinski T., Schmitt L., and Kunze K. Disability and quality of life in Charcot-Marie-Tooth disease type 1. J. Neurol. Neurosurg. Psychiatry 70 4 (2001) 548-550
63. Piper P., Dibble S., Dodd M., Weiss M., Slaughter R., and Paul S. The revised Piper fatigue scale: psychometric evaulation in women with breast cancer. Oncol. Nurs. Forum 25 (1998) 677-684
64. Piper P., Lindsey A., and Dodd M. The development of an instrument to measure the subjective dimension of fatigue. In: Funk S., Tornquist E., and Champagne M. (Eds). Keys aspects of comfort management of pain, fatigue and nausea (1989), Springer, New York 199-208
65. Robbins R.A., Simmons Z., Bremer B.A., Walsh S.M., and Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 56 4 (2001) 442-444
66. Rocha J.A., Reis C., Simoes F., Fonseca J., and Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J. Neurol. 252 12 (2005) 1435-1447
67. Romani A., Piccolo G., Bergamaschi R., Versino M., and Cosi V. A reliability study of impairment and disability scales for Myasthenia Gravis patients. Funct. Neurol. 17 3 (2002) 137-144
68. Rowland L.P., and Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344 22 (2001) 1688-1700
69. Rozman J., Bunc M., and Zupan A. Evaluation of the strength of elbow flexors in patients with neuromuscular diseases. J. Med. Eng. Technol. 25 6 (2001) 235-239
70. Ruhland J.L., and Shields R.K. The effects of a home exercise program on impairment and health-related quality of life in persons with chronic peripheral neuropathies. Phys. Ther. 77 10 (1997) 1026-1039
71. Scarmeas N., Shih T., Stern Y., Ottman R., and Rowland L.P. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 59 5 (2002) 773-775
72. Schanke A.K., and Stanghelle J.K. Fatigue in polio survivors. Spinal Cord 39 5 (2001) 243-251
73. Schanke A.K., Stanghelle J.K., Andersson S., Opheim A., Strom V., and Solbakk A.K. Mild versus severe fatigue in polio survivors: special characteristics. J. Rehabil. Med. 34 3 (2002) 134-140
74. Schulte-Mattler W.J., Muller T., Deschauer M., Gellerich F.N., Iaizzo P.A., and Zierz S. Increased metabolic muscle fatigue is caused by some but not all mitochondrial mutations. Arch. Neurol. 60 1 (2003) 50-58
75. Scott O.M., Vrbova G., Hyde S.A., and Dubowitz V. Responses of muscles of patients with Duchenne muscular dystrophy to chronic electrical stimulation. J. Neurol. Neurosurg. Psychiatry 49 12 (1986) 1427-1434
76. Sharma K.R., Kent-Braun J., Mynhier M.A., Weiner M.W., and Miller R.G. Excessive muscular fatigue in the postpoliomyelitis syndrome. Neurology 44 4 (1994) 642-646
77. Sharma K.R., Kent-Braun J.A., Majumdar S., Huang Y., Mynhier M., Weiner M.W., et al. Physiology of fatigue in amyotrophic lateral sclerosis. Neurology 45 4 (1995) 733-740
78. Sharma K.R., Mynhier M.A., and Miller R.G. Muscular fatigue in Duchenne muscular dystrophy. Neurology 45 2 (1995) 306-310
79. Simmons Z., Bremer B.A., Robbins R.A., Walsh S.M., and Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology 55 3 (2000) 388-392
80. Sivakumar K., Sinnwell T., Yildiz E., McLaughlin A., and Dalakas M.C. Study of fatigue in muscles of patients with postpolio syndrome by in vivo [31P]magnetic resonance spectroscopy. A metabolic cause for fatigue. Ann. NY Acad. Sci. 753 (1995) 397-401
81. Smets E.M., Garssen B., Bonke B., and De Haes J.C. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39 3 (1995) 315-325
82. Strohschein F.J., Kelly C.G., Clarke A.G., Westbury C.F., Shuaib A., and Chan K.M. Applicability, validity, and reliability of the Piper fatigue scale in postpolio patients. Am. J. Phys. Med. Rehabil. 82 2 (2003) 122-129
83. Taylor D.J., Kemp G.J., Woods C.G., Edwards J.H., and Radda G.K. Skeletal muscle bioenergetics in myotonic dystrophy. J. Neurol. Sci. 116 2 (1993) 193-200
84. Thompson R.T., Barton P.M., Marsh G.D., Cameron M.G., Gravelle D.G., Hsieh J.T., et al. Postpolio fatigue: a 31P magnetic resonance spectroscopy investigation. Orthopedics 14 11 (1991) 1263-1267
85. Todd G., Taylor J.L., and Gandevia S.C. Measurement of voluntary activation of fresh and fatigued human muscles using transcranial magnetic stimulation. J. Physiol. 551 Pt2 (2003) 661-671
86. Torres C., Moxley R.T., and Griggs R.C. Quantitative testing of handgrip strength, myotonia, and fatigue in myotonic dystrophy. J. Neurol. Sci. 60 1 (1983) 157-168
87. Trojan D.A., and Cashman N.R. Postpoliomyelitis syndrome. Muscle Nerve 31 (2005) 6-19
88. Trojan D.A., Gendron D., and Cashman N.R. Anticholinesterase-responsive neuromuscular junction transmission defects in postpoliomyelitis fatigue. J. Neurol. Sci. 114 (1993) 170-177
89. van der Kooi E.L., Lindeman E., and Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst. Rev. 1 (2005) (CD003907)
90. van der Werf S., Kalkman J., Bleijenberg G., van Engelen B., Schillings M., and Zwarts M. The relation between daytime sleepiness, fatigue, and reduced motivation in patients with adult onset myotonic dystrophy. J. Neurol. Neurosurg. Psychiatry 74 1 (2003) 138-139
91. Van Engelen B.G., Kalkman J.S., Schillings M.L., Van Der Werf S.P., Bleijenberg G., and Zwarts M.J. Fatigue in neuromuscular disease. Ned. Tijdschr. Geneeskd. 148 27 (2004) 1336-1341
92. Videler A.J., Beelen A., and Aufdemkampe G. de Groot ischiojambiers, Van Leemputte M. Hand strength and fatigue in patients with hereditary motor and sensory neuropathy (types I and II). Arch. Phys. Med. Rehabil. 83 9 (2002) 1274-1278
93. Vinci P., Esposito C., Perelli S.L., Antenor J.A., and Thomas F.P. Overwork weakness in Charcot-Marie-Tooth disease. Arch. Phys. Med. Rehabil. 84 6 (2003) 825-827
94. Younkin D.P., Berman P., Sladky J., Chee C., Bank W., and Chance B. 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology 37 1 (1987) 165-169
95. Zochodne D.W., Koopman W.J., Witt N.J., Thompson T., Driedger A.A., Gravelle D., et al. Forearm P-31 nuclear magnetic resonance spectroscopy studies in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 19 2 (1992) 174-179